NASDAQ: NGEN
Nervgen Pharma Revenue

Nervgen Pharma revenue was $0.00 for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, NGEN annual revenue was $0.0, with N/A growth year-over-year.

NGEN revenue history

Current Revenue
$0.0
Current Earnings
-$32.2M
Current Profit Margin
0%

Be the first to know when NGEN announces revenue.

NGEN Revenue History By Year

NGEN Yearly RevenueNGEN RevenueNGEN ChangeNGEN Revenue Growth
2025-12-31$0.00N/AN/A
2024-12-31$0.00N/AN/A
2023-12-31$0.00N/AN/A

1 of 1

Nervgen Pharma Revenue FAQ

What was NGEN's revenue last quarter?

Nervgen Pharma (NASDAQ: NGEN) reported Q4 2025 revenue of $0.00 up N/A year over year. In the same quarter last year, Nervgen Pharma's revenue was $0.00.

What was Nervgen Pharma's revenue in 2025?

Nervgen Pharma's annual revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.

How much does Nervgen Pharma make in a day?

Based on Nervgen Pharma annual revenue for the past two years, NGEN makes an average of $0.00 per day.

What was Nervgen Pharma's annual revenue growth in the past year?

As of Q2 2026, Nervgen Pharma's revenue has grown null year over year. Nervgen Pharma's revenue in the past year totaled $0.00.

How much does Nervgen Pharma make in a year?

Nervgen Pharma's revenue by year for the past two years is:
  • Nervgen Pharma's revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.
  • Nervgen Pharma's annual revenue for Dec 31, 2024 was $0.00, a N/A decrease from 2023.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.